Evidence map›Paper›PMID 31363170›Full record

ArticleBritish journal of cancer2019

Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma.

Thomas R Jeffry Evans, Masatoshi Kudo, Richard S Finn, Kwang-Hyub Han, Ann-Lii Cheng, Masafumi Ikeda, Silvija Kraljevic, Min Ren, Corina E Dutcus, Fabio Piscaglia and 1 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Thomas R Jeffry EvansUniversity of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK. j.evans@beatson.gla.ac.uk.
Masatoshi KudoDepartment of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
Richard S FinnDavid Geffen School of Medicine, UCLA Medical Center, Los Angeles, CA, USA.
Kwang-Hyub HanSeverance Hospital, Yonsei University, Seoul, South Korea.
Ann-Lii ChengNational Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan.
Masafumi IkedaDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Silvija KraljevicFormer employee of Eisai Ltd, Hatfield, UK.
Min RenEisai Inc., Woodcliff Lake, NJ, USA.
Corina E DutcusEisai Inc., Woodcliff Lake, NJ, USA.
Fabio PiscagliaUnit of Internal Medicine, University of Bologna, S.Orsola-Malpighi Hospital, Bologna, Italy.
Max W SungTisch Cancer Institute at Mount Sinai, New York, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This article was originally published under a standard license to Publish, but has now been made available under a CC BY license. The PDF and HTML versions of the paper have been modified accordingly.An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Identifiers

PMID31363170
PMCPMC6889263

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.